Difference between revisions of "Part:BBa K4165185"
(→Usage and Biology) |
|||
| (One intermediate revision by one other user not shown) | |||
| Line 16: | Line 16: | ||
<!-- --> | <!-- --> | ||
| − | <span class='h3bb'>Sequence and Features</span> | + | ===<span class='h3bb'>Sequence and Features</span>=== |
<partinfo>BBa_K4165185 SequenceAndFeatures</partinfo> | <partinfo>BBa_K4165185 SequenceAndFeatures</partinfo> | ||
| Line 28: | Line 28: | ||
Cheng, Y., Chen, Z., Liao, T., Lin, C., Shen, H., & Wang, Y. et al. (2017). An intranasally delivered peptide drug ameliorates cognitive decline in Alzheimer transgenic mice. EMBO Molecular Medicine, 9(5), 703-715. doi: 10.15252/emmm.201606666 | Cheng, Y., Chen, Z., Liao, T., Lin, C., Shen, H., & Wang, Y. et al. (2017). An intranasally delivered peptide drug ameliorates cognitive decline in Alzheimer transgenic mice. EMBO Molecular Medicine, 9(5), 703-715. doi: 10.15252/emmm.201606666 | ||
| + | |||
| + | Mamsa, S. S., & Meloni, B. P. (2021). Arginine and Arginine-Rich Peptides as Modulators of Protein Aggregation and Cytotoxicity Associated With Alzheimer’s Disease. Frontiers in Molecular Neuroscience. https://doi.org/10.3389/fnmol.2021.759729 | ||
Latest revision as of 17:45, 10 October 2022
Amyloid beta peptide 5 (R8-A𝛽 25-35)
This part encodes an Amyloid 𝛽 peptide which is the R8 peptide (BBa_K4165180) conjugated with Aß fragment (25-35). This peptide has the ability to bind to A𝛽 plaques inside the brain.
Usage and Biology
A bipartite peptide composed of two modules; a segment from the amyloid beta fibrils (Aß25-35) to allow peptide interaction with the fibrils, and a polyarginine peptide (R8) to act on inhibition of the self-aggregation of plaques.
Segments of amyloid beta fibrils are widely used as a recognition sequence for amyloid beta plaques inside the brain, they seemed to exert no cytotoxicity especially when bound to cationic arginine peptides.
Arginine (R) is a basic amino acid with the presence of a guanidino group at its aliphatic side chain. It is typically protonated at physiological pH where the guanidino group turns into a cationic guanidinium moiety that is highly stable and able to self-associate and cluster. These properties contribute to the intra- and intermolecular associations of arginine residues, as it provides a great capacity for electrostatic interactions (especially hydrogen-bonding) that results in a tendency to form stable clusters in solution.
Arginine has long been recognized as a chemical chaperone, with its ability to interact with and influence proteins in solution. In silico experiments have proved its ability to bind protein surfaces for a long time through its carboxyl and guanidinium groups, and form clusters through self-association with other arginine molecules. This has led to various in vitro experiments that proved the ability of arginine to suppress protein aggregations, which made it a very interesting candidate in the modulation of proteopathies correlated with Alzheimer’s disease.
Sequence and Features
- 10COMPATIBLE WITH RFC[10]
- 12COMPATIBLE WITH RFC[12]
- 21COMPATIBLE WITH RFC[21]
- 23COMPATIBLE WITH RFC[23]
- 25COMPATIBLE WITH RFC[25]
- 1000COMPATIBLE WITH RFC[1000]
References
Cheng, Y., Chen, Z., Liao, T., Lin, C., Shen, H., & Wang, Y. et al. (2017). An intranasally delivered peptide drug ameliorates cognitive decline in Alzheimer transgenic mice. EMBO Molecular Medicine, 9(5), 703-715. doi: 10.15252/emmm.201606666
Mamsa, S. S., & Meloni, B. P. (2021). Arginine and Arginine-Rich Peptides as Modulators of Protein Aggregation and Cytotoxicity Associated With Alzheimer’s Disease. Frontiers in Molecular Neuroscience. https://doi.org/10.3389/fnmol.2021.759729